Clinical calculator summary
PI-RADS v2.1 assessment category interpreter
Clinical calculator summary
PI-RADS v2.1 assessment category interpreter
An identity interpreter for the five ordinal PI-RADS v2.1 categories assigned by a radiologist.
Evidence-based context for fast calculator use
- Purpose:
- Display the official ordinal suspicion meaning without reconstructing MRI sequence scoring or adding clinical-management rules.
- Population:
- Treatment-naive patients undergoing prostate MRI for suspected clinically significant prostate cancer, with a radiologist-assigned PI-RADS v2.1 category.
- Factors:
- Exact assigned category 1-5, PI-RADS version 2.1 attribution, Ordinal suspicion meaning
- Reference:
- Turkbey B, et al. Eur Urol. 2019;76(3):340-351. DOI 10.1016/j.eururo.2019.02.033.
Pin your most used calculators here by clicking the star in the dropdown.
PI-RADS® v2.1 Assessment Category Interpreter
Clinical Context & Background
This route interprets a radiologist-assigned PI-RADS v2.1 assessment category from 1 through 5 for suspected clinically significant prostate cancer in a treatment-naive prostate gland. It does not derive a category from T2-weighted imaging, diffusion-weighted imaging, ADC, dynamic contrast enhancement, lesion zone, size, or other MRI findings.
In PI-RADS v2.1, clinically significant prostate cancer is defined on pathology as Gleason score at least 7, including qualifying 3+4 with a prominent but not predominant Gleason pattern 4 component, and/or tumor volume at least 0.5 cc, and/or extraprostatic extension. The category is ordinal suspicion, not a calibrated patient probability.
Formula Logic
Identity lookup: the exact radiologist-assigned PI-RADS v2.1 category 1-5 remains unchanged and maps to its official ordinal suspicion meaning.Reference Data
| PI-RADS v2.1 category | Suspicion level | Meaning for clinically significant prostate cancer |
|---|---|---|
| 1 | Very low | Highly unlikely |
| 2 | Low | Unlikely |
| 3 | Intermediate | Equivocal |
| 4 | High | Likely |
| 5 | Very high | Highly likely |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- After a radiologist has assigned a PI-RADS v2.1 assessment category on prostate MRI.
- For suspected clinically significant prostate cancer in a treatment-naive prostate gland.
How To Interpret
- Categories 1 through 5 represent increasing ordinal suspicion that clinically significant prostate cancer is present.
- The category is not a calibrated individual probability and is not modified by PSA density or other clinical variables in this interpreter.
What To Do Next
- Integrate the radiology report with clinical history, laboratory data, patient preferences, local expertise, and current multidisciplinary guidance outside this interpreter.
Limitations
- Does not assign PI-RADS from T2W, DWI/ADC, DCE, zone, lesion size, or MRI quality.
- Not for old or unknown PI-RADS versions or examinations without a radiologist-assigned v2.1 category.
- Not for post-treatment recurrence, active-surveillance progression, staging, histologic grading, numeric cancer risk, or management decisions.
- Does not generate a biopsy or treatment recommendation.
Validated Population
PI-RADS v2.1 scope: suspected clinically significant prostate cancer in treatment-naive prostate glands.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed PI-RADS v2.1 cases passed through visible production controls at Categories 1, 3, and 5.
- No unexpected N/A, literal undefined value, stale control, unsupported risk gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/pirads-Prostate-MRI-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during the route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/pirads-Prostate-MRI.json.
: Full validation test
- 128/128 engine, UI, equality, malformed-input, reset, trace, source, registry, isolation, report, history, and mirror assertions passed with zero category mismatch.
- This is source-to-code implementation verification, not independent clinical validation, calibrated patient probability, or management advice.
: Correction
- Locked the permanent route to interpretation of an already radiologist-assigned 2019 PI-RADS v2.1 assessment category; no MRI sequence-to-category derivation was added.
- Removed the category-3 default, Number coercion, NaN fallthrough, aliases, malformed acceptance, PSA-density/category conflation, and misleading full-algorithm claims.
- Restored the exact five ordinal meanings and complete csPCa definition, added source/version attribution and identity trace, and removed automated biopsy recommendations.
Included in the current validation report.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should PI-RADS® v2.1 Assessment Category Interpreter be used?
Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.
Can PI-RADS® v2.1 Assessment Category Interpreter determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.